African Journal of
Pharmacy and Pharmacology

  • Abbreviation: Afr. J. Pharm. Pharmacol.
  • Language: English
  • ISSN: 1996-0816
  • DOI: 10.5897/AJPP
  • Start Year: 2007
  • Published Articles: 2194

Full Length Research Paper

Comparative effect on liver fibrosis of bicyclol and silymarin

Liping Wang
  • Liping Wang
  • Department of Pharmacy, Chengdu Jinjiang Hospital for Women and Children Health, Chengdu, Sichuan, 610021, China.
  • Google Scholar
Li Zhang
  • Li Zhang
  • Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, 610041, China.
  • Google Scholar
Kelan Gan
  • Kelan Gan
  • Department of Pharmacy, Chengdu Jinjiang Hospital for Women and Children Health, Chengdu, Sichuan, 610021, China.
  • Google Scholar
Xiaoping Hua
  • Xiaoping Hua
  • Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, 610041, China.
  • Google Scholar
Ying Xiao
  • Ying Xiao
  • Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, 610041, China.
  • Google Scholar
Yikun Shi
  • Yikun Shi
  • Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, 610041, China.
  • Google Scholar
Zhenghuai Tan
  • Zhenghuai Tan
  • Institute of Traditional Chinese Medicine Pharmacology and Toxicology, Sichuan Academy of Chinese Medicine Sciences, Chengdu, Sichuan, 610041, China.
  • Google Scholar


  •  Received: 16 October 2019
  •  Accepted: 17 December 2019
  •  Published: 31 May 2020

Abstract

Bicyclol and silymarin are widely used in the treatment of various liver diseases; however, there is no report on comparative effect of them on liver fibrosis. To compare their liver protective effect, liver fibrosis rats induced by bile duct ligation (BDL) were orally treated with 100 mg/kg bicyclol and 100 mg/kg silymarin respectively for 4 weeks. Liver index, liver function activities, inflammatory biomarkers, fibrotic biomarkers and liver histopathology were assessed. BDL induced marked histopathological changes in liver tissues coupled with changes in serum biochemistry. Furthermore, hepatic content of hydroxyproline, transforming growth factor-beta1 (TGF-β1), and interleukin-6 (IL-6) were elevated, together with a reduction of interleukin-1 alpha (IL-1α) and interleukin-4 (IL-4) in the liver. In addition, BDL increased the expression of alpha-smooth muscle actin (α-SMA). Treatment with bicyclol or silymarin protected against BDL induced liver fibrosis, as proved by the alleviation of inflammatory and fibrotic biomarkers. Overall, our results indicated that the effect of bicyclol was better than that of silymarin.

Key words: Liver fibrosis, bile duct ligation, bicyclol, silymarin, comparative effect.